

Guy Wj Makin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8862653/guy-wj-makin-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31
papers

882
citations

17
h-index

29
g-index

32
ext. papers

1,000
ext. citations

6.6
avg, IF

3.92
L-index

#	Paper	IF	Citations
31	Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients. <i>European Journal of Cancer</i> , 2021 ,	7.5	4
30	Constitutional de novo deletion CNV encompassing predisposes to diffuse hyperplastic perilobar nephroblastomatosis (HPLN). <i>Journal of Medical Genetics</i> , 2021 , 58, 581-585	5.8	0
29	The efficacy of interactive group psychoeducation for children with leukaemia: A randomised controlled trial. <i>Patient Education and Counseling</i> , 2021 , 104, 3008-3015	3.1	0
28	Detection of Circulating and Disseminated Neuroblastoma Cells Using the ImageStream Flow Cytometer for Use as Predictive and Pharmacodynamic Biomarkers. <i>Clinical Cancer Research</i> , 2020 , 26, 122-134	12.9	8
27	Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10507-10507	2.2	2
26	Randomized comparisons of bevacizumab (B) and irinotecan (I), added to temozolomide (T), in children with relapsed or refractory high-risk neuroblastoma (RR-HRNB): First survival results of the ITCC-SIOPEN BEACON-Neuroblastoma phase II trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10501-10501	2.2	2
25	Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. <i>European Journal of Cancer</i> , 2020 , 141, 82-91	7.5	9
24	Report of Resistant Varicella Zoster Infection Treated With Donor Lymphocyte Infusion in a Pediatric Oncology Patient. <i>Pediatric Infectious Disease Journal</i> , 2019 , 38, 513-515	3.4	1
23	PEPtalk2: results of a pilot randomised controlled trial to compare VZIG and aciclovir as postexposure prophylaxis (PEP) against chickenpox in children with cancer. <i>Archives of Disease in Childhood</i> , 2019 , 104, 25-29	2.2	5
22	Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study. <i>Cancer Research and Treatment</i> , 2018 , 50, 148-155	5.2	31
21	TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. <i>Pharmacogenetics and Genomics</i> , 2017 , 27, 213-222	1.9	33
20	Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. <i>British Journal of Cancer</i> , 2016 , 115, 1048-1057	8.7	40
19	A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. <i>Clinical Cancer Research</i> , 2015 , 21, 267-73	12.9	37
18	Categorising paediatric prescribing errors by junior doctors through prescribing competency assessment: does assessment reflect actual practice?. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 1163-6	2.8	6
17	Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1Alpha. <i>PLoS ONE</i> , 2013 , 8, e65304	3.7	49
16	Sperm banking in the United Kingdom is feasible in patients 13 years old or older with cancer. <i>Journal of Urology</i> , 2012 , 188, 594-7	2.5	31
15	Alteration of cellular behavior and response to PI3K pathway inhibition by culture in 3D collagen gels. <i>PLoS ONE</i> , 2012 , 7, e48024	3.7	60

14	A phase I trial of AT9283 (a selective inhibitor of Aurora kinases) given for 72 hours every 21 days via intravenous infusion in children and adolescents with relapsed and refractory solid tumours.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 9542-9542	2.2	
13	Bioengineering approaches to study multidrug resistance in tumor cells. <i>Integrative Biology (United Kingdom)</i> , 2011 , 3, 529-39	3.7	17
12	The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 2373-83	6.1	23
11	Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. <i>Journal of Clinical Investigation</i> , 2011 , 121, 1075-87	15.9	43
10	Outcome of gram negative infection in immunocompromised children. <i>Pediatric Blood and Cancer</i> , 2008 , 51, 499-503	3	5
9	Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 2241-50	6.1	71
8	Acquired chemosensitivity after insect bite in a boy with leukaemia. <i>British Journal of Haematology</i> , 2006 , 134, 244-5	4.5	2
7	Detection of recurrence in childhood solid tumors. <i>Cancer</i> , 2005 , 103, 1274-9	6.4	21
6	Recent advances in understanding apoptosis: new therapeutic opportunities in cancer chemotherapy. <i>Trends in Molecular Medicine</i> , 2003 , 9, 251-5	11.5	31
5	Targeting apoptosis in cancer chemotherapy. <i>Expert Opinion on Therapeutic Targets</i> , 2002 , 6, 73-84	6.4	33
4	Apoptosis and cancer chemotherapy. <i>Trends in Cell Biology</i> , 2001 , 11, S22-6	18.3	109
3	Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy?. <i>Breast Cancer Research</i> , 2001 , 3, 150-3	8.3	35
2	Apoptosis and cancer chemotherapy. <i>Cell and Tissue Research</i> , 2000 , 301, 143-52	4.2	167
1	Salmonella duban in an infant. <i>Lancet, The</i> , 1996 , 348, 200	4.0	7